PreprintCited by 514SARS-CoV-2 and COVID-19 ResearchCOVID-19 epidemiological studiesCOVID-19 Clinical Research Studies

The DOI matches its Crossref record; 14 of the 16 references it cites were found in a registry or an index.

Decreased SARS-CoV-2 viral load following vaccination

Open access

Levine-Tiefenbrun, Matan, Yelin, Idan, Katz, Rachel, Herzel, Esma, Golan, Ziv, Schreiber, Licita, Wolf, Tamar, Nadler, Varda, Ben-Tov, Amir, Kuint, Jacob, Gazit, Sivan, Patalon, Tal, Chodick, Gabriel, Kishony, Roy·2021·Nature Medicine

DOI 10.1101/2021.02.06.21251283

Preprint — published as 10.1038/s41591-021-01316-7 · Paper page

Open this paper in CoChat — free account Open PDF

Abstract

Beyond their substantial protection of individual vaccinees, it is hoped that the COVID-19 vaccines would reduce viral load in breakthrough infections thereby further suppress onward transmission. Here, analyzing positive SARS-CoV-2 test results following inoculation with the BNT162b2 mRNA vaccine, we find that the viral load is reduced 4-fold for infections occurring 12-28 days after the first dose of vaccine. These reduced viral loads hint to lower infectiousness, further contributing to vaccine impact on virus spread.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1101/2021.02.06.21251283

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Temporal dynamics in viral shedding and transmissibility of COVID-19
He, X., Lau, E. H. Y., Wu, P., Deng, X., Wang, J., Hao, X., Lau, Y. C., Wong, J. Y., Guan, Y., Tan, X., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0869-5 · Cited by 4,300
A guide to vaccinology: from basic principles to new developments
Pollard, A. J., & Bijker, E. M. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00479-7 · Cited by 1,593
Rethinking Covid-19 Test Sensitivity — A Strategy for Containment
Mina, M. J., Parker, R., & Larremore, D. B. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2025631 · Cited by 715
SARS-CoV-2 viral load predicts COVID-19 mortality
Pujadas, E., Chaudhry, F. F., McBride, R. B., Richter, F., Zhao, S., Wajnberg, A., Nadkarni, G. N., Glicksberg, B. S., Houldsworth, J., & Cordon‐Cardo, C. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30354-4 · Cited by 534
Evaluation of COVID-19 RT-qPCR Test in Multi sample Pools
Yelin, I., Aharony, N., Tamar, E. S., Argoetti, A., Messer, E., Berenbaum, D., Shafran, E., Kuzli, A., Gandali, N., Shkedi, O., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa531 · Cited by 450
Self-citation
Understanding COVID-19 vaccine efficacy
Lipsitch, M., & Dean, N. E. (2020) · Science · doi:10.1126/science.abe5938 · Cited by 230
Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization
Chodick, G., Tene, L., Patalon, T., Gazit, S., Ben‐Tov, A., Cohen, D., & Muhsen, K. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.15985 · Cited by 189
Self-citation
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Transmission Dynamics Should Inform Policy
Çevik, M., Marcus, J. L., Buckee, C. O., & Smith, T. C. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1442 · Cited by 141
SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn
Connors, M., Graham, B. S., Lane, H. C., & Fauci, A. S. (2021) · Annals of Internal Medicine · doi:10.7326/m21-0111 · Cited by 71

Show all 16 references

Research works printed but not linked: 2

Chodcik, G. et al. The effectiveness of the first dose of BNT162 b 2 vaccine in reducing SARS-CoV-2 infection 13-24 days after immunization: real-world evidence. medRxiv 2021.01.27.21250612 (2021). · DOI
Levine-Tiefenbrun, M. et al. Association of COVID-19 RT-qPCR test false-negative rate with patient age, sex and time since diagnosis. medRxiv (2020). · DOI

Sorted by citations

Drug delivery systems for RNA therapeutics
Paunovska, K., Loughrey, D., & Dahlman, J. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00439-4 · Cited by 1,349
Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape
Tregoning, J. S., Flight, K. E., Higham, S. L., Wang, Z., & Pierce, B. F. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00592-1 · Cited by 1,146
Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review
Fiolet, T., Kherabi, Y., MacDonald, C.-J., Ghosn, J., & Peiffer-Smadja, N. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.10.005 · Cited by 911
Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study
Singanayagam, A., Hakki, S., Dunning, J. W., Madon, K. J., Crone, M. A., Koycheva, A., Derqui, N., Barnett, J. L., Whitfield, M. G., Varro, R., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00648-4 · Cited by 733
Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus
Raman, B., Bluemke, D. A., Lüscher, T. F., & Neubauer, S. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac031 · Cited by 717
Immunological mechanisms of vaccine-induced protection against COVID-19 in humans
Sadarangani, M., Marchant, A., & Kollmann, T. R. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00578-z · Cited by 560
Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines
Thompson, M. G., Burgess, J. L., Naleway, A. L., Tyner, H. L., Yoon, S. K., Meece, J. K., Olsho, L. E. W., Caban-Martinez, A. J., Fowlkes, A., Lutrick, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107058 · Cited by 482
Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants
Eyre, D. W., Taylor, D., Purver, M., Chapman, D., Fowler, T., Pouwels, K. B., Walker, A. S., & Peto, T. E. A. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116597 · Cited by 464
Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals
Kustin, T., Harel, N., Finkel, U., Perchik, S., Harari, S., Tahor, M., Caspi, I., Levy, R., Leshchinsky, M., Ken Dror, S., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01413-7 · Cited by 373
Effect of Vaccination on Household Transmission of SARS-CoV-2 in England
Harris, R., Hall, J., Zaidi, A., Andrews, N. J., Dunbar, J. K., & Dabrera, G. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2107717 · Cited by 350
Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273
Steensels, D., Pierlet, N., Penders, J., Mesotten, D., & Heylen, L. (2021) · JAMA · doi:10.1001/jama.2021.15125 · Cited by 351
Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study
Chia, P. Y., Ong, S. W. X., Chiew, C. J., Ang, L. W., Chavatte, J., Mak, T. M., Cui, L., Kalimuddin, S., Chia, W. N., Tan, C. W., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.11.010 · Cited by 328
Household transmission of SARS-CoV-2 Omicron variant of concern subvariants BA.1 and BA.2 in Denmark
Lyngse, F. P., Kirkeby, C., Denwood, M. J., Christiansen, L. E., Mølbak, K., Møller, C. H., Skov, R. L., Krause, T. G., Rasmussen, M., Sieber, R. N., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33498-0 · Cited by 300
Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors
Shroff, R. T., Chalasani, P., Wei, R., Pennington, D., Quirk, G., Schoenle, M. V., Peyton, K. L., Uhrlaub, J. L., Ripperger, T. J., Jergović, M., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01542-z · Cited by 237
Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2
Levine-Tiefenbrun, M., Yelin, I., Alapi, H., Katz, R., Herzel, E., Kuint, J., Chodick, G., Gazit, S., Patalon, T., & Kishony, R. (2021) · Nature Medicine · doi:10.1038/s41591-021-01575-4 · Cited by 222
Self-citation
Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization
Lapuente, D., Fuchs, J., Willar, J., Antão, A. V., Eberlein, V., Uhlig, N., Issmail, L., Schmidt, A. P., Oltmanns, F., Peter, A. S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27063-4 · Cited by 218
Vaccine Effectiveness of the First Dose of ChAdox1 nCOV-19 and BNT162b2 Against SARS-CoV-2 Infection in Residents of Long Term Care Facilities (VIVALDI Study)
Shrotri, M., Krutikov, M., Palmer, T., Giddings, R., Azmi, B., Subbarao, S., Fuller, C., Irwin-Singer, A., Davies, D., Tut, G., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00289-9 · Cited by 184
The Effectiveness of the Two-Dose BNT162b2 Vaccine: Analysis of Real-World Data
Chodick, G., Tene, L., Rotem, R. S., Patalon, T., Gazit, S., Ben-Tov, A., Weil, C., Goldshtein, I., Twig, G., Cohen, D., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab438 · Cited by 176
Self-citation
In vivo kinetics of SARS-CoV-2 infection and its relationship with a person’s infectiousness
Ke, R., Zitzmann, C., Ho, D. D., Ribeiro, R. M., & Perelson, A. S. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2111477118 · Cited by 175
Drug delivery systems for CRISPR-based genome editors
Madigan, V. J., Zhang, F., & Dahlman, J. E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00762-x · Cited by 193
Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity
Hagin, D., Freund, T., Navon, M., Halperin, T., Adir, D., Marom, R., Levi, I., Benor, S., Alcalay, Y., & Freund, N. T. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.05.029 · Cited by 174
COVID-19 vaccines and decreased transmission of SARS-CoV-2
Vitiello, A., Ferrara, F., Troiano, V., & Porta, R. L. (2021) · Inflammopharmacology · doi:10.1007/s10787-021-00847-2 · Cited by 168
Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel
Prunas, O., Warren, J. L., Crawford, F. W., Gazit, S., Patalon, T., Weinberger, D. M., & Pitzer, V. E. (2022) · Science · doi:10.1126/science.abl4292 · Cited by 153
Self-citation
Combining spike- and nucleocapsid-based vaccines improves distal control of SARS-CoV-2
Dangi, T., Class, J., Palacio, N. M., Richner, J. M., & Penaloza‐MacMaster, P. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109664 · Cited by 139
Quantifying the relationship between SARS-CoV-2 viral load and infectiousness
Marc, A., Kerioui, M., Blanquart, F., Bertrand, J., Mitjà, J., Corbacho‐Monné, M., Marks, M., & Guedj, J. (2021) · eLife · doi:10.7554/elife.69302 · Cited by 146
The use of RNA-based treatments in the field of cancer immunotherapy
Chehelgerdi, M., & Chehelgerdi, M. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01807-w · Cited by 149
Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization
Patel, M. K., Bergeri, I., Bresee, J., Cowling, B. J., Crowcroft, N. S., Fahmy, K., Hirve, S. S., Kang, G., Katz, M. A., Lanata, C. F., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.05.099 · Cited by 146
Addressing vaccine hesitancy and access barriers to achieve persistent progress in Israel’s COVID-19 vaccination program
Rosen, B., Waitzberg, R., Israeli, A., Hartal, M., & Davidovitch, N. (2021) · Israel Journal of Health Policy Research · doi:10.1186/s13584-021-00481-x · Cited by 148
Waning of IgG, Total and Neutralizing Antibodies 6 Months Post-Vaccination with BNT162b2 in Healthcare Workers
Bayart, J., Douxfils, J., Gillot, C., David, C., Mullier, F., Elsen, M., Eucher, C., Eeckhoudt, S. V., Roy, T., Gérin, V., et al. (2021) · Vaccines · doi:10.3390/vaccines9101092 · Cited by 133
A Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Disease
Higdon, M. M., Wahl, B., Jones, C. B., Rosen, J. G., Truelove, S., Baidya, A., Nande, A., ShamaeiZadeh, P. A., Walter, K. K., Feikin, D. R., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac138 · Cited by 133
Reactance revisited: Consequences of mandatory and scarce vaccination in the case of COVID‐19
Sprengholz, P., Betsch, C., & BOHM, R. M. (2021) · Applied Psychology Health and Well-Being · doi:10.1111/aphw.12285 · Cited by 131
Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva
Ketas, T. J., Chaturbhuj, D. N., Portillo, V. M. C., Francomano, E., Golden, E. B., Chandrasekhar, S., Debnath, G., Diaz-Tapia, R., Yasmeen, A., Kramer, K. D., et al. (2021) · Pathogens and Immunity · doi:10.20411/pai.v6i1.441 · Cited by 126
Adenovirus type 5 SARS-CoV-2 vaccines delivered orally or intranasally reduced disease severity and transmission in a hamster model
Langel, S. N., Johnson, S., Martinez, C. I., Tedjakusuma, S. N., Peinovich, N., Dora, E. G., Kuehl, P. J., Irshad, H., Barrett, E. G., Werts, A. D., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn6868 · Cited by 121
Should children be vaccinated against COVID-19?
Zimmermann, P., Pittet, L. F., Finn, A. H. R., Pollard, A. J., & Curtis, N. C. (2021) · Archives of Disease in Childhood · doi:10.1136/archdischild-2021-323040 · Cited by 131
Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study
Haas, E. J., McLaughlin, J. M., Khan, F. L., Angulo, F. J., Anis, E., Lipsitch, M., Singer, S. R., Mircus, G., Brooks, N., Smaja, M., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00566-1 · Cited by 131
Factors influencing SARS-CoV-2 RNA concentrations in wastewater up to the sampling stage: A systematic review
Bertels, X., Demeyer, P., den Bogaert, S. V., Boogaerts, T., van Nuijs, A. L. N., Delputte, P., & Lahousse, L. (2022) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2022.153290 · Cited by 120
Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination
Cobey, S. E., Larremore, D. B., Grad, Y. H., & Lipsitch, M. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00544-9 · Cited by 119
Long Covid: where we stand and challenges ahead
Mantovani, A., Morrone, M. C., Patrono, C., Santoro, M., Schiaffino, S., Remuzzi, G., Bussolati, G., On behalf of the Covid-19 Commission of the Accademia Nazionale dei Lincei, Cappuccinelli, P., Fitzgerald, G., et al. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-01052-6 · Cited by 124
Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel
Regev-Yochay, G., Amit, S., Bergwerk, M., Lipsitch, M., Leshem, E., Kahn, R., Lustig, Y., Cohen, C., Doolman, R., Ziv, A., et al. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100150 · Cited by 111
An analysis of 45 large-scale wastewater sites in England to estimate SARS-CoV-2 community prevalence
Morvan, M., Jacomo, A. L., Souque, C., Wade, M. J., Hoffmann, T., Pouwels, K. B., Lilley, C. J., Singer, A. C., Porter, J., Evens, N. P., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31753-y · Cited by 100
Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals
Milman, O., Yelin, I., Aharony, N., Katz, R., Herzel, E., Ben‐Tov, A., Kuint, J., Gazit, S., Chodick, G., Patalon, T., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01407-5 · Cited by 112
Self-citation
COVID-19 in the 47 countries of the WHO African region: a modelling analysis of past trends and future patterns
Cabore, J. W., Karamagi, H. C., Kipruto, H. K., Mungatu, J. K., Asamani, J. A., Droti, B., Titi-ofei, R., Seydi, A. B. W., Kidane, S. N., Balde, T., et al. (2022) · The Lancet Global Health · doi:10.1016/s2214-109x(22)00233-9 · Cited by 108
SARS-CoV-2 placentitis, stillbirth, and maternal COVID-19 vaccination: clinical–pathologic correlations
Schwartz, D. A., Mulkey, S. B., & Roberts, D. J. (2022) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2022.10.001 · Cited by 103
Prevention of host-to-host transmission by SARS-CoV-2 vaccines
Mostaghimi, D., Valdez, C. N., Larson, H. T., Kalinich, C. C., & Iwasaki, A. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00472-2 · Cited by 97
The Implementation of Mass-Vaccination against SARS-CoV-2: A Systematic Review of Existing Strategies and Guidelines
Hasan, T., Beardsley, J., Marais, B. J., Nguyen, T. A., & Fox, G. J. (2021) · Vaccines · doi:10.3390/vaccines9040326 · Cited by 97
Humoral and Cellular Response Following Vaccination With the BNT162b2 mRNA COVID-19 Vaccine in Patients Affected by Primary Immunodeficiencies
Amodio, D., Ruggiero, A., Sgrulletti, M., Pighi, C., Cotugno, N., Medri, C., Rocchi, F., Colagrossi, L., Russo, C., Zaffina, S., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.727850 · Cited by 94
Anti-SARS-CoV-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID-19 mRNA BNT162b2 Vaccination
Salvagno, G. L., Henry, B. M., Piazza, G. D., Pighi, L., NITTO, S. D., Bragantini, D., Gianfilippi, G. L., & Lippi, G. (2021) · Diagnostics · doi:10.3390/diagnostics11050832 · Cited by 90
The success of SARS-CoV-2 vaccines and challenges ahead
Subbarao, K. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.06.016 · Cited by 92
The impact of SARS-CoV-2 vaccination on Alpha and Delta variant transmissionPreprint
Eyre, D. W., Taylor, D., Purver, M. B., Chapman, D., Fowler, T., Pouwels, K. B., Walker, A. S., & Peto, T. (2021) · medRxiv · doi:10.1101/2021.09.28.21264260 · Cited by 88
Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections
Abu-Raddad, L. J., Chemaitelly, H. S., Ayoub, H. H., Tang, P., Coyle, P. V., Hasan, M. R., Yassine, H. M., Benslimane, F. M., Al-Khatib, H. A., Kanaani, Z. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28199-7 · Cited by 80
Model-driven mitigation measures for reopening schools during the COVID-19 pandemic
McGee, R. S., Homburger, J. R., Williams, H., Bergstrom, C. T., & Zhou, A. Y. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2108909118 · Cited by 80
Covid-19: variants and vaccination
Darby, A. C., & Hiscox, J. A. (2021) · BMJ · doi:10.1136/bmj.n771 · Cited by 76
B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19
Zollner, A., Watschinger, C., Rössler, A., Farcet, M. R., Penner, A., Böhm, V., Zollner-Kiechl, S., Stampfel, G., Hintenberger, R., Tilg, H., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103539 · Cited by 75
Improved control of SARS-CoV-2 by treatment with a nucleocapsid-specific monoclonal antibody
Dangi, T., Sanchez, S., Class, J., Richner, M., Visvabharathy, L., Chung, Y. R., Bentley, K., Stanton, R. J., Koralnik, I. J., Richner, J. M., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci162282 · Cited by 69
Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges
Amanatidou, E., Gkiouliava, A., Pella, E., Serafidi, M., Tsilingiris, D., Vallianou, N. G., Karampela, Ι., & Dalamaga, Μ. (2022) · Metabolism Open · doi:10.1016/j.metop.2022.100180 · Cited by 78
Long-Term Autoimmune Inflammatory Rheumatic Outcomes of COVID-19
Kim, M. S., Lee, H., Lee, S. W., Kwon, R., Rhee, S. Y., Lee, J. A., Koyanagi, A., Smith, L., Fond, G. B., Boyer, L., et al. (2024) · Annals of Internal Medicine · doi:10.7326/m23-1831 · Cited by 75
The indirect effect of mRNA-based COVID-19 vaccination on healthcare workers’ unvaccinated household members
Salo, J., Hägg, M., Kortelainen, M., Leino, T. M., Saxell, T., Siikanen, M., & Sääksvuori, L. (2022) · Nature Communications · doi:10.1038/s41467-022-28825-4 · Cited by 71
mRNA vaccines: Past, present, future
Karam, M., & Daoud, G. (2022) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2022.05.003 · Cited by 76
Highly Specific Memory B Cells Generation after the 2nd Dose of BNT162b2 Vaccine Compensate for the Decline of Serum Antibodies and Absence of Mucosal IgA
Mortari, E. P., Russo, C., Vinci, M. R., Terreri, S., Salinas, A. F., Piccioni, L., Alteri, C., Colagrossi, L., Coltella, L., Ranno, S., et al. (2021) · Cells · doi:10.3390/cells10102541 · Cited by 72
Relaxing restrictions at the pace of vaccination increases freedom and guards against further COVID-19 waves
Bauer, S., Contreras, S., Dehning, J., Linden, M., Iftekhar, E. N., Mohr, S., Olivera‐Nappa, Á., & Priesemann, V. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009288 · Cited by 73
A Systematic Review and Meta-Analysis of Inpatient Mortality Associated With Nosocomial and Community COVID-19 Exposes the Vulnerability of Immunosuppressed Adults
Ponsford, M., Ward, T., Stoneham, S. M., Dallimore, C. M., Sham, D., Osman, K., Barry, S. M., Jolles, S. R. A., Humphreys, I. R., & Farewell, D. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.744696 · Cited by 68
Six months of COVID vaccines: what 1.7 billion doses have taught scientists
Ledford, H. K. (2021) · Nature · doi:10.1038/d41586-021-01505-x · Cited by 68
Glycaemic control is associated with SARS-CoV-2 breakthrough infections in vaccinated patients with type 2 diabetes
Marfella, R., Sardu, C., D’Onofrio, N., Prattichizzo, F., Scisciola, L., Messina, V., Grotta, R. L., Balestrieri, M. L., Maggi, P., Claudio Napoli, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30068-2 · Cited by 70
SARS-CoV-2 vaccine breakthrough infections with the alpha variant are asymptomatic or mildly symptomatic among health care workers
Rovida, F., Cassaniti, I., Paolucci, S., Percivalle, E., Sarasini, A., Piralla, A., Giardina, F., Sammartino, J. C., Ferrari, A., Bergami, F., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26154-6 · Cited by 62
Can COVID vaccines stop transmission? Scientists race to find answers
Mallapaty, S. (2021) · Nature · doi:10.1038/d41586-021-00450-z · Cited by 67
A novel passive sampling approach for SARS-CoV-2 in wastewater in a Canadian province with low prevalence of COVID-19
Hayes, E. K., Sweeney, C. L., Anderson, L. E., Li, B., Erjavec, G. B., Gouthro, M., Krkošek, W. H., Stoddart, A. K., & Gagnon, G. A. (2021) · Environmental Science Water Research & Technology · doi:10.1039/d1ew00207d · Cited by 65
COVID-19 vaccine acceptance among high-risk populations in Uganda
Bongomin, F., Olum, R., Biraro, I. A., Nakwagala, F. N., Hassan, K. H., Nassozi, D. R., Kaddumukasa, M., Byakika‐Kibwika, P., Kiguli, S., & Kirenga, B. (2021) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361211024376 · Cited by 60
Similarity of Protection Conferred by Previous SARS-CoV-2 Infection and by BNT162b2 Vaccine: A 3-Month Nationwide Experience From Israel
Goldberg, Y., Mandel, M., Woodbridge, Y., Fluss, R., Novikov, I., Yaari, R., Ziv, A., Freedman, L. S., & Huppert, A. (2022) · American Journal of Epidemiology · doi:10.1093/aje/kwac060 · Cited by 64
Waning of SARS-CoV-2 booster viral-load reduction effectiveness
Levine-Tiefenbrun, M., Yelin, I., Alapi, H., Herzel, E., Kuint, J., Chodick, G., Gazit, S., Patalon, T., & Kishony, R. (2022) · Nature Communications · doi:10.1038/s41467-022-28936-y · Cited by 63
Self-citation
Vaccine rollout strategies: The case for vaccinating essential workers early
Mulberry, N., Tupper, P. F., Kirwin, E. M., McCabe, C. J., & Colijn, C. (2021) · PLOS Global Public Health · doi:10.1371/journal.pgph.0000020 · Cited by 67
Impact of SARS-CoV-2 Gamma lineage introduction and COVID-19 vaccination on the epidemiological landscape of a Brazilian city
Banho, C. Á., Sacchetto, L., Campos, G. R. F., Bittar, C., Possebon, F. S., Ullmann, L. S., Marques, B. D. C., da Silva, G. C. D., Moraes, M. M., Parra, M. C. P., et al. (2022) · Communications Medicine · doi:10.1038/s43856-022-00108-5 · Cited by 63
Can a combination of vaccination and face mask wearing contain the COVID‐19 pandemic?
Brüssow, H., & Zuber, S. (2021) · Microbial Biotechnology · doi:10.1111/1751-7915.13997 · Cited by 66
Postvaccination COVID‐19 infection is associated with reduced mortality in patients with cirrhosis
John, B. V., Deng, Y., Schwartz, K. B., Taddei, T. H., Kaplan, D. E., Martin, P. B., Chao, H., & Dahman, B. A. (2022) · Hepatology · doi:10.1002/hep.32337 · Cited by 56
Efficacy of COVID-19 vaccines: From clinical trials to real life
Deplanque, D., & Launay, O. (2021) · Therapies · doi:10.1016/j.therap.2021.05.004 · Cited by 57
Epidemics, the Ising-model and percolation theory: A comprehensive review focused on Covid-19
Mello, I. F., Squillante, L., Gomes, G. O., Seridonio, A. C. F., & Souza, M. D. (2021) · Physica A Statistical Mechanics and its Applications · doi:10.1016/j.physa.2021.125963 · Cited by 56
Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose
Rénia, L., Goh, Y. S., Rouers, A., Bert, N. L., Chia, W. N., Chavatte, J., Fong, S., Chang, Z. W., Zhuo, N. Z., Tay, M. Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32312-1 · Cited by 62
Delivery Routes for COVID-19 Vaccines
Park, J. H., & Lee, H. K. (2021) · Vaccines · doi:10.3390/vaccines9050524 · Cited by 53
The Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Antigen Testing (June 2021)
Hanson, K. E., Altayar, O., Caliendo, A. M., Arias, C. A. D., Englund, J. A., Hayden, M. K., Lee, M. J., Loeb, M. B., Patel, R., Alayli, A. E., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab557 · Cited by 60
A Systematic Review of the Sex and Gender Reporting in COVID-19 Clinical Trials
Heidari, S., Palmer-Ross, A., & Goodman, T. (2021) · Vaccines · doi:10.3390/vaccines9111322 · Cited by 54
Signals of hope: gauging the impact of a rapid national vaccination campaign
Shilo, S., Rossman, H., & Segal, E. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00531-0 · Cited by 53
Viral load dynamics of SARS-CoV-2 Delta and Omicron variants following multiple vaccine doses and previous infection
Woodbridge, Y., Amit, S., Huppert, A., & Kopelman, N. M. (2022) · Nature Communications · doi:10.1038/s41467-022-33096-0 · Cited by 52
Treatment-induced and Pre-existing Anti-peg Antibodies: Prevalence, Clinical Implications, and Future Perspectives
Gaballa, S. A., Shimizu, T., Ando, H., Takata, H., Emam, S. E., Ramadan, E., Naguib, Y. W., Mady, F. M., Khaled, K. A., & Ishida, T. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.11.001 · Cited by 60
Transmission of SARS-CoV-2 variant B.1.1.7 among vaccinated health care workers
Ιωάννου, Π., Karakonstantis, S., Astrinaki, E., Saplamidou, S., Vitsaxaki, E., Hamilos, G., Sourvinos, G., & Kofteridis, D. P. (2021) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2021.1945139 · Cited by 52
Direct and Indirect Effectiveness of mRNA Vaccination against Severe Acute Respiratory Syndrome Coronavirus 2 in Long-Term Care Facilities, Spain
Monge, S., Olmedo, C., Alejos, B., Lapeña, M. F., Sierra, M. J., Limia, A., & COVID-19 registries study group (2021) · Emerging infectious diseases · doi:10.3201/eid2710.211184 · Cited by 51
SARS-CoV-2 transmission, persistence of immunity, and estimates of Omicron’s impact in South African population cohorts
Sun, K., Tempia, S., Kleynhans, J., von Gottberg, A., McMorrow, M. L., Wolter, N., Bhiman, J. N., Moyes, J., du Plessis, M., Carrim, M., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo7081 · Cited by 52
Booster Vaccination to Reduce SARS-CoV-2 Transmission and Infection
Wald, A. (2022) · JAMA · doi:10.1001/jama.2021.23726 · Cited by 52
Quality and Adoption of COVID-19 Tracing Apps and Recommendations for Development: Systematic Interdisciplinary Review of European Apps
Kahnbach, L., Lehr, D., Brandenburger, J., Mallwitz, T., Jent, S., Hannibal, S., Funk, B., & Janneck, M. (2021) · Journal of Medical Internet Research · doi:10.2196/27989 · Cited by 51
Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents
Bošnjak, B., Odak, I., Barros‐Martins, J., Sandrock, I., Hammerschmidt, S. I., Permanyer, M., Patzer, G. E., Georgiev, H., Jauregui, R. G., Tscherne, A., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.772240 · Cited by 50
Duration of viral shedding and culture positivity with postvaccination SARS-CoV-2 delta variant infections
Siedner, M. J., Boucau, J., Gilbert, R. F., Uddin, R., Luu, J., Haneuse, S., Vyas, T. D., Reynolds, Z., Iyer, S. L., Chamberlin, G. C., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.155483 · Cited by 47
Efficacy Estimates for Various COVID-19 Vaccines: What we Know from the Literature and ReportsPreprint
Shapiro, J., Dean, N. E., Madewell, Z. J., Yang, Y., Halloran, M. E., & Longini, I. M. (2021) · medRxiv · doi:10.1101/2021.05.20.21257461 · Cited by 46
Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021
Xu, K., Dai, L., & Gao, G. F. (2021) · International Immunology · doi:10.1093/intimm/dxab061 · Cited by 48
Accuracy and ease-of-use of seven point-of-care SARS-CoV-2 antigen-detecting tests: A multi-centre clinical evaluation
Krüger, L. J., Tanuri, A., Lindner, A. K., Gaeddert, M., Köppel, L., Tobian, F., Brümmer, L. E., Klein, J. A. F., Lainati, F., Schnitzler, P., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103774 · Cited by 48
Long-Term Safety of Rituximab (Risks of Viral and Opportunistic Infections)
Varley, C. D., & Winthrop, K. L. (2021) · Current Rheumatology Reports · doi:10.1007/s11926-021-01037-3 · Cited by 47
Revisiting COVID-19 policies: 10 evidence-based recommendations for where to go from here
Halperin, D. T., Hearst, N., Hodgins, S., Bailey, R. C., Klausner, J. D., Jackson, H., Wamai, R. G., Ladapo, J. A., Over, M., Baral, S., et al. (2021) · BMC Public Health · doi:10.1186/s12889-021-12082-z · Cited by 47
Efficacy of mRNA, adenoviral vector, and perfusion protein COVID-19 vaccines
Zinatizadeh, M. R., Zarandi, P. K., Zinatizadeh, M., Yousefi, M. H., Amani, J., & Rezaei, N. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112527 · Cited by 51
Understanding the dynamic relation between wastewater SARS-CoV-2 signal and clinical metrics throughout the pandemic
Hegazy, N., Cowan, A., D’Aoust, P. M., Mercier, É., Towhid, S. T., Jia, J., Wan, S., Zhang, Z., Kabir, M. P., Fang, W., et al. (2022) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2022.158458 · Cited by 43
Predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California
Servellita, V., Morris, M. K., Sotomayor-González, A., Gliwa, A. S., Torres, E., Brazer, N., Zhou, A. Y., Hernandez, K., Sankaran, M., Wang, B., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-021-01041-4 · Cited by 46
Divalent siRNAs are bioavailable in the lung and efficiently block SARS-CoV-2 infection
Hariharan, V. N., Shin, M., Chang, C., O’Reilly, D., Biscans, A., Yamada, K., Guo, Z., Somasundaran, M., Tang, Q., Monopoli, K. R., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2219523120 · Cited by 49
Indirect Protection by Reducing Transmission: Ending the Pandemic With Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination
Richterman, A. G., Meyerowitz, E. A., & Çevik, M. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab259 · Cited by 45
COVID-19 Booster Vaccination Hesitancy in the United States: A Multi-Theory-Model (MTM)-Based National Assessment
Batra, K., Sharma, M., Dai, C., & Khubchandani, J. (2022) · Vaccines · doi:10.3390/vaccines10050758 · Cited by 44

Authors: Levine-Tiefenbrun, M., Yelin, I., Katz, R., Herzel, E., Golan, Z., Schreiber, L., Wolf, T., Nadler, V., Ben-Tov, A., Kuint, J., Gazit, S., Patalon, T., Chodick, G., & Kishony, R.
Affiliations: Technion – Israel Institute of Technology (IL)
Maccabi Healthcare Services (IL)
Tel Aviv University (IL)
Corresponding author: Yelin, Idan
Kishony, Roy
ORCID: Levine-Tiefenbrun, Matan
Yelin, Idan
Katz, Rachel
Herzel, Esma
Wolf, Tamar
Gazit, Sivan
Patalon, Tal
Chodick, Gabriel
Kishony, Roy
Venue: Nature Medicine
Publisher: openRxiv
Published: 2021-02-08
Volume: 27
Issue: 5
Pages: 790-792
ISSN: 1078-8956 (ISSN-L)
DOI: 10.1101/2021.02.06.21251283
OpenAlex: W3150351745
Cited by: 514
References: 16
Citations by year: 2026: 4 · 2025: 12 · 2024: 19 · 2023: 67 · 2022: 166 · 2021: 242
FWCI: 39.10
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Nature Medicine (publishedVersion)
medRxiv (acceptedVersion, cc-by-nc)
PubMed (publishedVersion)
Funders: Israel Science Foundation (3633/19)
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Keywords: SARS-CoV-2, COVID-19 pandemic, BNT162b2, mRNA vaccines, breakthrough infection, viral load, infectiousness, transmission reduction, vaccine effectiveness, real-world data
MeSH terms: COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Vaccination, Viral Load, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Decreased SARS-CoV-2 viral load following vaccination

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks